Page 15 - Read Online

Bozzetti et al. Neuroimmunol Neuroinflammation 2021;8:1-13 I http://dx.doi.org/10.20517/2347-8659.2020.26 Page 11

12. Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, et al. Association of blood and cerebrospinal fluid tau level and other
biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 2019;76:969-77.
13. Steinacker P, Anderl-Straub S, Diehl-Schmid J, Semler E, Uttner I, et al; FTLDc Study Group. Serum neurofilament light chain in
behavioral variant frontotemporal dementia. Neurology 2018;91:e1390-401.
14. Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 2019;9:1167.
15. Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, et al. Serum NFL discriminates Parkinson disease from atypical
parkinsonisms. Neurology 2019;92:e1479-86.
16. Posti JP, Takala RSK, Lagerstedt L, Dickens AM, Hossain I, et al. Correlation of blood biomarkers and biomarker panels with traumatic
findings on computed tomography after traumatic brain injury. J Neurotrauma 2019;36:2178-89.
17. Korley FK, Goldstick J, Mastali M, Van Eyk JE, Barsan W, et al. Serum NfL (Neurofilament Light Chain) levels and incident stroke in
adults with diabetes mellitus. Stroke 2019;50:1669-75.
18. Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, et al. Serum and cerebrospinal neurofilament light chain levels in patients
with acquired peripheral neuropathies. J Peripher Nerv Syst 2018;23:174-7.
19. Mariotto S, Gajofatto A, Zuliani L, Zoccarato M, Gastaldi M, et al. Serum and CSF neurofilament light chain levels in antibody-mediated
encephalitis. J Neurol 2019;266:1643-8.
20. Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, et al. Neurofilament light chain predicts disease activity in relapsing-
remitting MS. Neurol Neuroimmunol Neuroinflamm 2017;5:e422.
21. Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, et al. Increased plasma neurofilament light chain concentration correlates with
severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 2019;7:5.
22. Mariotto S, Sechi E, Ferrari S. Serum neurofilament light chain studies in neurological disorders, hints for interpretation. J Neurol Sci
2020;416:116986.
23. Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, et al; Controlled High-Risk Avonex Multiple Sclerosis Prevention
Study in Ongoing Neurological Surveillance Investigators. Association between immediate initiation of intramuscular interferon beta-1a
at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple
Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183-90.
24. Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S. Radiologically isolated syndrome--incidental magnetic
resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler 2013;19:271-80.
25. Håkansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease
activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol 2017;24:703-12.
26. Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, et al. Cerebrospinal fluid neurofilament light levels mark grey matter
volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2018;24:1039-45.
27. Pawlitzki M, Sweeney-Reed CM, Bittner D, Lux A, Vielhaber S, et al. CSF-Progranulin and neurofilament light chain levels in patients
with radiologically isolated syndrome-sign of inflammation. Front Neurol 2018;9:1075.
28. Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, et al. Neurofilament light chain and oligoclonal bands are
prognostic biomarkers in radiologically isolated syndrome. Brain 2018;141:1085-93.
29. Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, et al; International Clinically Isolated Syndrome Study Group.
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry
2016;87:126-9.
30. Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, et al. Serum neurofilament is associated with progression of brain atrophy and
disability in early MS. Neurology 2017;88:826-31.
31. Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, et al. Serum neurofilament light chain levels in patients with presymptomatic
multiple sclerosis. JAMA Neurol 2019;77:58-64.
32. Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, et al. Prognostic value of serum neurofilaments in patients with clinically
isolated syndromes. Neurology 2019;92:e733-41.
33. Saleem S, Anwar A, Fayyaz M, Anwer F, Anwar F. An overview of therapeutic options in relapsing-remitting multiple sclerosis. Cureus
2019;11:e5246.
34. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions.
Neurology 2014;83:278-86.
35. Domingues RB, Fernandes GBP, Leite FBVM, Senne C. Neurofilament light chain in the assessment of patients with multiple sclerosis.
Arquivos de Neuro-Psiquiatria 2019;77:436-41.
36. Martínez MA, Olsson B, Bau L, Matas E, Cobo Calvo A, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in
multiple sclerosis. Mult Scler 2015;21:550-61.
37. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in
multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4.
38. Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, et al. Blood neurofilament light chain as a biomarker of MS disease activity
and treatment response. Neurology 2019;92:e1007-15.
39. Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, et al. Axonal damage in relapsing multiple sclerosis is markedly
reduced by natalizumab. Ann Neurol 2011;69:83-9.
40. Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, et al. Blood neurofilament light as a potential endpoint in Phase 2 studies
in MS. Ann Clin Transl Neurol 2019;6:1081-9.